Boehringer Ingelheim and Micromet, Inc. have entered into a collaboration agreement for the research, development and commercialization of a new BiTE antibody for the treatment of multiple myeloma. Micromet will be responsible for discovery of the BiTE antibody and the two companies will jointly conduct further preclinical studies. BI will be responsible for all manufacturing activities, clinical development and worldwide commercialization subject to Micromet’s co-promotion right in th...